title: Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials.
abstract: Community-acquired pneumonia (CAP) is a leading cause of morbidity and mortality throughout the world. To investigate whether moxifloxacin monotherapy is associated with better clinical outcomes than other antibiotics recommended for CAP among adults with mild-to-moderate or severe  CAP, we performed a meta-analysis. MEDLINE, EMBASE, Web of Science, and the Cochrane Library were searched for randomized control trials (RCTs). The efficacy and safety of moxifloxacin were compared with other antimicrobial agents used to treat CAP. Fourteen RCTs, consisting of 6923 total  patients, were included in the meta-analysis. No difference was found regarding the incidence of adverse events and mortality between moxifloxacin and the compared regimens. We found that moxifloxacin is as effective and well-tolerated as other recommended antibiotics for the treatment of  CAP and possesses a better pathogen eradication rate than beta-lactam-based therapy.
authors.affiliation: Department of Respiratory Diseases, General Hospital of Chinese People’s Liberation Army, Beijing, China.
authors.forename: Xin
authors.initials: X
authors.lastname: Yuan
authors.forename: Bei-Bei
authors.initials: BB
authors.lastname: Liang
authors.forename: Rui
authors.initials: R
authors.lastname: Wang
authors.forename: You-Ning
authors.initials: YN
authors.lastname: Liu
authors.forename: Chun-Guang
authors.initials: CG
authors.lastname: Sun
authors.forename: Yun
authors.initials: Y
authors.lastname: Cai
authors.forename: Xu-Hong
authors.initials: XH
authors.lastname: Yu
authors.forename: Nan
authors.initials: N
authors.lastname: Bai
authors.forename: Tie-Mei
authors.initials: TM
authors.lastname: Zhao
authors.forename: Jun-Chang
authors.initials: JC
authors.lastname: Cui
authors.forename: Liang-An
authors.initials: LA
authors.lastname: Chen
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D017714:Community-Acquired Infections / Q000188:drug therapy; D024841:Fluoroquinolones; D006801:Humans; D000077266:Moxifloxacin; D018410:Pneumonia, Bacterial / Q000188:drug therapy*; D011804:Quinolines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin